Killer artificial antigen-presenting cells: A novel strategy to delete specific T cells

Blood

Volumn 111, Issue 7, 2008, Pages 3546-3552

  Schütz, Christian ^a,b   Fleck, Martin ^a   Mackensen, Andreas ^a,c   Zoso, Alessia ^b,d   Halbritter, Dagmar ^a   Schneck, Jonathan P ^b   Oelke, Mathias ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; FAS ANTIGEN; FAS LIGAND; HLA A2 ANTIGEN; HLA A2 ANTIGEN IMMUNOGLOBULIN G1 FAS ANTIGEN MONOCLONAL ANTIBODY IGM CONJUGATE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IGM; UNCLASSIFIED DRUG; MICROSPHERE;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CELL DEATH; COCULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; ALLOTRANSPLANTATION; CELL CULTURE; CHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METHODOLOGY; TIME;

ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD95; AUTOIMMUNE DISEASES; CELL DEATH; CELLS, CULTURED; FAS LIGAND PROTEIN; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN M; LYMPHOCYTE DEPLETION; MICROSPHERES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 43549095277     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-113522     Document Type: Article

References (56)

1. Toungouz M, Donckier V, Goldman M. Tolerance induction in clinical transplantation: the pending questions. Transplantation. 2003;75:58S-60S.
2. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation: how much of the promise has been realized? Nat Med. 2005;11:605-613.
3. Anderson G, Moore NC, Owen JJ; Jenkinson EJ. Cellular interactions in thymocyte development. Annu Rev Immunol. 1996;14:73-99.
4. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000;407:789-795.
5. Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood. 2Q05;105:1396-1404.
6. Bluestone JA, Tang Q. How do CD4+CD25 + regulatory T cells control autoimmunity? Curr Opin Immunol. 2005;17:638-642.
7. Munz G, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. 2005;202:203-207.
8. Cooper MD, Alder MN. The evolution of adaptive immune systems. Cell. 2006;124:815-822.
9. Griffith TS, BrunnerT Fletcher SM, Green DR. Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995; 270:1189-1192.
10. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med. 1996;2:1361-1366.
11. Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol. 1998;10:564-572.
12. Igney FH; Krammer PH. Tumor counterattack: fact or fiction? Cancer Immunol Immunother. 2005;54:1127-1136.
13. Matsue H, Matsue K, Walters M, et al. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med. 1999;5:930-937.
14. Matsue H, Matsue K, Kusuhara M. et al. Immunosuppressive properties of GD95L-transduced '"killer' hybrids created by fusing donor- and recipient-derived dendritic cells. Blood. 2001 ;98: 3465-3472.
15. Kusuhara M, Matsue K, Edelbaum D, et al. Killing of naive T cells by CD95L-transfected dendritic cells (DG): in vivo study using killer DC-DC hybrids and CD4(+)T cells from D011.10 mice. Eur J Immunol. 2002;32:1035-1043.
16. Georgantas RW, III, Leong KW, August JT. Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum Gene Ther. 2000:11:851-858.
17. Min WR Gorczynski R, Huang XY et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol. 2000; 164:161-167.
18. Zhang HG, Liu D. Heike Y, et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol. 1998; 16:1045-1049.
19. Buonocore S, Paulart F, Le Moine A, et al. Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood. 2003;101:1469-1476.
20. Buonocore S, Flamand V, Claessen N, et al. Dendritic cells overexpressing Fas-ligand induce pulmonary vasculitis in mice. Glin Exp Immunol. 2004;137:74-80.
21. Strauss G, Osen W, Knape I. et al. Membrane- bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity. Gell Death Differ. 2007:14:480-488.
22. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 200523:515-548.
23. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol. 2000:164:3095-3101.
24. Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-lg-coated artificial antigen-presenting cells. Nat Med. 2003:9:619-624.
25. Hoves S, Krause SW, Halbritter D, et al. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer ARC. J Immunol. 2003;170:5406-5413.
26. Hoves S, Krause SW, Herfarth H, et al. Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/ CD95L)-expressing Killer-dendritic cells. Immu-nobiology. 2004;208:463-475.
27. Fischer K, Mackensen A. The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods. 2003;31:135-142.
28. Fischer K, Voelkl S, Berger J. et al. Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood. 2006;108:4094-4101.
29. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for de-granulation. J Immunol Methods. 2003;281:65-78.
30. Dulat HJ, von Grumbkow C, Baars W, et al. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol. 2001 ;31:2217-2226.
31. Whartenby KA, Straley EE, Kim H, et al. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term en-graftment in a murine model of allogeneic bone marrow transplantation. Blood. 2002:100:3147-3154.
32. Elhalel MD, Huang JH, Schmidt W, Rachmilewitz J, Tykocinski ML. CTLA-4: FasL induces alloantigen-specific hyporesponsiveness. J Immunol. 2003:170:5842-5850.
33. Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immuno-modulation: FasL-decorated cells prevent islet graft rejection. Immunity. 2002;17:795-808.
34. Yagita H, Seino K, Kayagaki N, Okumura K. CD95 ligand in graft rejection. Nature. 1996;379: 682.
35. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 1996;273:109-112.
36. Fleck M, Zhang HG, Kern ER, et al. Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum. 2001 44:964-973.
37. Wu B, Wu JM, Miagkov A, et al. Specific immunotherapy by genetically engineered APCs: the ''guided missile" strategy. J Immunol. 2001 ;166: 4773-4779.
38. Zhang HG, Fleck M, Kern ER, et al. Antigen presenting cells expressing Fas ligand down- modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest. 2000:105: 813-821.
39. Wolfe T, Asseman C, Hughes A, et al. Reduction of antiviral CDS lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J Immunol. 2002;169: 4867-4872.
40. Yuan RR, Wong P, McDevitt MR, et al. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood. 2004;104:2397- 2402.
41. Hess PR, Barnes C, Woolard MD, et al. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein, saporin. Blood. 2007;109: 3300-3307.
42. Nagata S. Apoptosis by death factor. Cell. 1997; 88:355-365.
43. Shen HM. Pervaiz S. TN F receptor superfamily-induced cell death: redox-dependent execution. FASEB J. 2006;20:1589-1598.
44. Huang JH, Tykocinski ML. CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. Int Immunol. 2001;13:529-539.
45. van Endert P, HassainyaY, Lindo V, et al. HLA class I epitope discovery in type 1 diabetes. Ann NY Acad Sci. 2006;1079:190-197.
46. Toma A, Haddouk S, Briand JP, et al. Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients. Proc Natl Acad Sci USA. 2005:102:10581-10586.
47. Pinkse GG, Tysma OH, Bergen CA, et al. Autoreactive CDS T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U SA. 2005;102:18425-18430.
48. Panagiotopoulos C, Qin H, Tan R, Verchere GB. Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes. 2003;52:2647-2651.
49. Panina-Bordignon P, Lang R, van Endert PM, et al. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med. 1995;181:1923-1927.
50. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054-1057.
51. Rufer N, Wolpert E, Helg C, et al. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation. 1998;66:910-916.
52. Niland B, Banki K, Biddison WE, Perl A. CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J Immunol. 2005;175:8365- 8378.
53. Zang YC, Li S, Rivera VM, et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. 2004;172:5120-5127.
54. Hershko AY, Naparstek Y. Autoimmunity in the era of genomics and proteomics. Autoimmun Rev. 2006;5:230-233.
55. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002:2:85-95.
56. Goldberg J, Shrikant P, Mescher MF. In vivo augmentation of tumor-specific CTL responses by class l/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol. 2003:170:228-235.